Jennifer Lester Email Address

Senior Vice President, Information Technology and Informatics

Juno Therapeutics, Inc. is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Its other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16/IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial for treatment of various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of adult myeloid leukemia, myelodysplasic syndrome and chronic myeloid leukemia.

Accomplished IT, informatics, and data strategy leader with over 25 years of experience…